Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Postmenopausal syndrome.

Dalal PK, Agarwal M.

Indian J Psychiatry. 2015 Jul;57(Suppl 2):S222-32. doi: 10.4103/0019-5545.161483. Review.

2.

In silico analysis of the molecular mechanism of postmenopausal osteoporosis.

Liu Y, Wang Y, Yang N, Wu S, Lv Y, Xu L.

Mol Med Rep. 2015 Nov;12(5):6584-90. doi: 10.3892/mmr.2015.4283.

3.

Influence of body weight on the biochemical indicators in menopause.

Rosic M, Rosic S, Samardzic R, Kendic S.

Mater Sociomed. 2014 Apr;26(2):93-5. doi: 10.5455/msm.2014.26.93-95.

4.

Effect of isoflavone soy protein supplementation on endometrial thickness, hyperplasia, and endometrial cancer risk in postmenopausal women: a randomized controlled trial.

Quaas AM, Kono N, Mack WJ, Hodis HN, Felix JC, Paulson RJ, Shoupe D.

Menopause. 2013 Aug;20(8):840-4. doi: 10.1097/GME.0b013e3182804353.

5.

Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr.

Endocr Rev. 2013 Apr;34(2):171-208. doi: 10.1210/er.2012-1008. Review.

6.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM; AACE Osteoporosis Task Force..

Endocr Pract. 2010 Nov-Dec;16 Suppl 3:1-37. No abstract available.

7.

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations.

Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM.

Endocr Pract. 2010 Nov-Dec;16(6):1016-9. No abstract available.

8.

Estrogen, hormonal replacement therapy and cardiovascular disease.

Yang XP, Reckelhoff JF.

Curr Opin Nephrol Hypertens. 2011 Mar;20(2):133-8. doi: 10.1097/MNH.0b013e3283431921. Review.

9.

Dose-dependent cardiac effect of oestrogen replacement in mice post-myocardial infarction.

Zhan E, Keimig T, Xu J, Peterson E, Ding J, Wang F, Yang XP.

Exp Physiol. 2008 Aug;93(8):982-93. doi: 10.1113/expphysiol.2008.042788.

10.

Should symptomatic menopausal women be offered hormone therapy?

Lobo RA, BĂ©lisle S, Creasman WT, Frankel NR, Goodman NF, Hall JE, Ivey SL, Kingsberg S, Langer R, Lehman R, McArthur DB, Montgomery-Rice V, Notelovitz M, Packin GS, Rebar RW, Rousseau M, Schenken RS, Schneider DL, Sherif K, Wysocki S.

MedGenMed. 2006;8(3):40. Review.

11.

Canadian Consensus Conference on osteoporosis, 2006 update.

Brown JP, Fortier M, Frame H, Lalonde A, Papaioannou A, Senikas V, Yuen CK; Osteoporosis Guidelines Committee..

J Obstet Gynaecol Can. 2006 Feb;28(2 Suppl 1):S95-112. English, French.

12.

The 2002 Canadian bone densitometry recommendations: take-home messages.

Khan AA, Brown JP, Kendler DL, Leslie WD, Lentle BC, Lewiecki EM, Miller PD, Nicholson RL, Olszynski WP, Watts NB.

CMAJ. 2002 Nov 12;167(10):1141-5. No abstract available.

13.

Menopause and hormone-replacement therapy: Part 2. Hormone-replacement therapy regimens.

Ratner S, Ofri D.

West J Med. 2001 Jul;175(1):32-4. No abstract available.

14.

Delayed oral estradiol combined with leuprolide increases endometriosis-related pain.

Hurst BS, Gardner SC, Tucker KE, Awoniyi CA, Schlaff WD.

JSLS. 2000 Apr-Jun;4(2):97-101.

15.

Hormone replacement therapy: where are we now?

Stuenkel C, Barrett-Connor E.

West J Med. 1999 Jul;171(1):27-30. Review. No abstract available.

16.

Hormone replacement therapy.

Barrett-Connor E.

BMJ. 1998 Aug 15;317(7156):457-61. Review. No abstract available.

Items per page

Supplemental Content

Support Center